自身免疫性肝炎的发病机制与治疗现状研究进展

摘要/Abstract

摘要： 自身免疫性肝炎(Autoimmune hepatitis, AIH)是一种原因不明的进展性肝病。目前认为是遗传、免疫和环境因素共同作用的结果,尤其是环境因素在AIH发病中的作用越来越受到关注。AIH的治疗方法主要有标准药物治疗、替代治疗和肝脏移植,但都有一定的局限性。本文对AIH的发病机制和治疗现状作简要综述,为AIH新靶点治疗研究提供参考依据。

关键词: 自身免疫性肝炎, 遗传因素, 免疫因素, 环境因素, 治疗

高璇, 张翠丽, 曾涛. 自身免疫性肝炎的发病机制与治疗现状研究进展[J]. 肝脏, 2022, 27(8): 928-931.

[1] Tanaka A. Autoimmune Hepatitis: 2019 Update. Gut Liver, 2020, 14: 430-438.
[2] Mieli-Vergani G, Vergani D, Czaja AJ, et al. Autoimmune hepatitis. Nat Rev Dis Primers, 2018, 4: 18017.
[3] Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology, 2010, 51: 2193-2213.
[4] Webb GJ, Hirschfield GM, Krawitt EL, et al. Cellular and Molecular Mechanisms of Autoimmune Hepatitis. Annu Rev Pathol, 2018, 13: 247-292.
[5] Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology, 2010, 139: 58-72.
[6] Nunes MEG, Rosa DV, Fagundes EDT, et al. HLA-DRB1 gene polymorphisms in pediatric patients with type 1 autoimmune hepatitis and type 1 autoimmune hepatitis overlap syndrome with autoimmune cholangitis. Arq Gastroenterol, 2019, 56: 146-150.
[7] Agarwal K, Czaja AJ, Jones DE, et al. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphisms and susceptibility to type 1 autoimmune hepatitis. Hepatology, 2000, 31: 49-53.
[8] Herkel J. Regulatory T Cells in Hepatic Immune Tolerance and Autoimmune Liver Diseases. Dig Dis, 2015, 33: 70-74.
[9] Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. Cell, 2010, 140: 845-858.
[10] Beringer A, Miossec P. IL-17 and IL-17-producing cells and liver diseases, with focus on autoimmune liver diseases. Autoimmun Rev, 2018, 17: 1176-1185.
[11] Liu Y, Yan W, Yuan W, et al. Treg/Th17 imbalance is associated with poor autoimmune hepatitis prognosis. Clin Immunol, 2019, 198: 79-88.
[12] 张磊, 董砚虎.维生素D抗感染机制研究进展.中华内分泌代谢杂志, 2021, 37: 168-171.
[13] Thiele GM, Duryee MJ, Willis MS, et al. Autoimmune hepatitis induced by syngeneic liver cytosolic proteins biotransformed by alcohol metabolites. Alcohol Clin Exp Res, 2010, 34: 2126-2136.
[14] Czaja AJ, Montano-Loza AJ. Evolving Role of Vitamin D in Immune-Mediated Disease and Its Implications in Autoimmune Hepatitis. Dig Dis Sci, 2019, 64: 324-344.
[15] Sucher E, Sucher R, Gradistanac T, et al. Autoimmune Hepatitis-Immunologically Triggered Liver Pathogenesis-Diagnostic and Therapeutic Strategies. J Immunol Res, 2019, 2019: 9437043.
[16] Vergani D, Mieli-Vergani G. Aetiopathogenesis of autoimmune hepatitis. World J Gastroenterol, 2008, 14: 3306-3312.
[17] Holdener M, Hintermann E, Bayer M, et al. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med, 2008, 205: 1409-1422.
[18] Wei Y, Li Y, Yan L, et al. Alterations of gut microbiome in autoimmune hepatitis. Gut, 2020, 69: 569-577.
[19] Manfredo VS, Hiltensperger M, Kumar V, et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science, 2018, 359: 1156-1161.
[20] Yuksel M, Wang Y, Tai N, et al. A novel "humanized mouse" model for autoimmune hepatitis and the association of gut microbiota with liver inflammation. Hepatology, 2015, 62: 1536-1550.
[21] Zahs A, Cook RT, Waldschimdt TJ, et al. Alcohol and inflammation and infection: clinical and experimental systems--summary of the 2010 Alcohol and Immunology Research Interest Group Meeting. Alcohol, 2012, 46: 147-153.
[22] Castiella A, Zapata E, Lucena MI, et al. Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease. World J Hepatol, 2014, 6: 160-168.
[23] Bogdanos DP, Dalekos GN. Enzymes as target antigens of liver-specific autoimmunity: the case of cytochromes P450s. Curr Med Chem, 2008, 15: 2285-2292.
[24] 段金楠, 蔡群, 王浩, 等.维生素D在自身免疫性肝病中的研究进展.中国微生态学杂志, 2021, 33: 614-617.
[25] Almeida MLLK, Lima LA, Alexandre DAPE, et al. Vitamin D (VD3) antioxidative and anti-inflammatory activities: Peripheral and central effects. Eur J Pharmacol, 2020, 879: 173099.
[26] Udomsinprasert W, Jittikoon J. Vitamin D and liver fibrosis: Molecular mechanisms and clinical studies. Biomed Pharmacother, 2019, 109: 1351-1360.
[27] 自身免疫性肝炎诊断和治疗共识(2015).中华传染病杂志, 2016, 34: 193-208.
[28] Czaja AJ. Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions. Gut Liver, 2016, 10: 177-203.
[29] Manns MP, Woynarowski M, Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology, 2010, 139: 1198-1206.
[30] Terziroli BB, Mieli-Vergani G, Vergani D. Autoimmune hepatitis: Standard treatment and systematic review of alternative treatments. World J Gastroenterol, 2017, 23: 6030-6048.
[31] Pape S, Schramm C, Gevers TJ. Clinical management of autoimmune hepatitis. United European Gastroenterol J, 2019, 7: 1156-1163.
[32] Zachou K, Gatselis NK, Arvaniti P, et al. A real-world study focused on the long-term efficacy of mycophenolate mofetil as first-line treatment of autoimmune hepatitis. Aliment Pharmacol Ther, 2016, 43: 1035-1047.
[33] Pape S, Nevens F, Verslype C, et al. Profiling the patient with autoimmune hepatitis on calcineurin inhibitors: a real-world-experience. Eur J Gastroenterol Hepatol, 2020, 32: 727-732.
[34] Tanaka A. Emerging novel treatments for autoimmune liver diseases. Hepatol Res, 2019, 49: 489-499.

自身免疫性肝炎的发病机制与治疗现状研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	孙悦, 孟方圆, 苑广菲, 高沿航. 酒精性肝炎的治疗进展[J]. 肝脏, 2022, 27(8): 849-852.
[2]	张磊, 黄育红, 罗凌, 汪丽萍, 方春华, 冉斌, 李应. 长期抗病毒治疗的慢性乙型肝炎患者血清TIMP-1和M-CSF水平变化[J]. 肝脏, 2022, 27(8): 863-867.
[3]	王利慧, 王荣希, 赵泽源, 郭振凯. 失代偿期乙型肝炎肝硬化患者门静脉血栓形成的临床意义[J]. 肝脏, 2022, 27(8): 874-876.
[4]	刘海霞, 段忠辉, 赖曼, 徐曼曼, 孟庆华, 陈煜. 319例肝病患者持续肾脏替代治疗的管路寿命及影响因素分析[J]. 肝脏, 2022, 27(8): 898-902.
[5]	苏雨, 孙小怡, 王倩怡, 赵新颜, 贾继东. 既往乙型肝炎病毒感染对自身免疫性肝炎治疗应答及预后的影响[J]. 肝脏, 2022, 27(7): 789-794.
[6]	凌霞, 田尧. 熊去氧胆酸联合泼尼松龙规范化治疗原发性胆汁性胆管炎合并自身免疫性肝炎的疗效和安全性[J]. 肝脏, 2022, 27(7): 814-817.
[7]	冉君, 屈献乐, 肖彬彬, 马红梅. 肝细胞癌免疫微环境与免疫抑制治疗的研究进展[J]. 肝脏, 2022, 27(7): 825-828.
[8]	施莉琴, 周柳青, 张晓琴, 叶晴, 周计雪. 药物诱导的AIH-PBC重叠综合征1例[J]. 肝脏, 2022, 27(7): 829-830.
[9]	李伟. 长期白蛋白治疗用于失代偿性肝硬化研究新进展[J]. 肝脏, 2022, 27(6): 617-619.
[10]	徐旭, 范建高. 非酒精性脂肪性肝病相关肝细胞癌面临的挑战[J]. 肝脏, 2022, 27(6): 620-621.
[11]	曾伟兰, 汪艳. 肝性脑病降氨治疗进展[J]. 肝脏, 2022, 27(6): 622-624.
[12]	黄鑫昱, 苏盛元, 王开琛, 王甘露. 巨噬细胞在肝癌发生、发展中的作用机制及其靶向治疗研究进展[J]. 肝脏, 2022, 27(6): 708-711.
[13]	李玉川, 王建设. 儿童肝病紧急事件的早期识别和处理[J]. 肝脏, 2022, 27(5): 505-507.
[14]	苑广菲, 孙悦, 孟方园, 高沿航. 酒精性肝病未被满足的临床需求与挑战[J]. 肝脏, 2022, 27(5): 508-510.
[15]	宋方彬, 李善宝, 徐军明. 肝移植治疗肝内胆管癌的现状与挑战[J]. 肝脏, 2022, 27(5): 514-515.